Immunoglobulin G4 (IgG4) Related Disease

Immunoglobulin G4 (IgG4) Related Disease

About this clinical trial

There are currently no medicinal products approved for the treatment of IgG4-RD. The majority of cases follow a relapsing course that can lead to permanent tissue damage with potential morbidity and mortality. This project aims to develop an effective product. 

The purpose of this study is to better understand the safety and side effects of  Inebilizumab and to find out if it helps people with IgG4 related disease.  

Patients Required

Estimated completion

December 2025

Total participants required


Study location

The Wesley Hospital

Trial title

A Phase 3, Randomized, Double-blind, Multicenter, Placebo-Controlled Study of Inebilizumab Efficacy and Safety in Immunoglobulin G4-related disease (IgG4Related Disease (MITIGATE).


Adults aged ≥ 18 years who have recently active IgG4-RD (initial diagnosis or flare) that requires new or ongoing treatment, are at high risk of future flare, and meet the 2019 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR)IgG4-RD classification criteria.

Additional information

You can find out more about the WVE-004 trial by visiting the ClinicalTrials.gov website.

Lead investigator

Dr Daman Langguth

If you would like more information about this clinical trial, please complete the Immunoglobulin G4-related disease (IgG4) Related Disease contact


Wesley Medical Research

Scroll to Top